MedTrace Logo

Vascular Improvement With Olmesartan Medoxomil Study

NCT00772499 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2008-10-15

No results posted yet for this study

Summary

The purpose of this study is to compare in patients with primary hypertension, the non-blood pressure lowering effects of one-year therapy with olmesartan medoxomil vs. those of atenolol on changes in the vascular structure and function.

Conditions

Interventions

DRUG

olmesartan medoxomil + hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure

Tablets and capsules for oral administration once or twice daily for up to 52 weeks

DRUG

atenolol+ hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure

Tablets and capsules for oral administration once or twice daily for up to 52 weeks

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-11-30
Primary Completion
2005-07-31
Completion
2005-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00772499 on ClinicalTrials.gov